Division of Medical Oncology, Department of Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea.
J Korean Med Sci. 2013 Oct;28(10):1549-51. doi: 10.3346/jkms.2013.28.10.1549. Epub 2013 Sep 25.
Diarrhea is a common adverse event of docetaxel with 20%-40% of incidence and severe diarrhea occurs in 5%-6%. Several treatment guidelines for chemotherapy induced diarrhea (CID) exist, however the prophylaxis for that is not well known. We describe a new prophylactic approach for the CID with loperamide. A 72-yr-old male patient with stage IV non-small-cell lung cancer developed diarrhea repeatedly after docetaxel-cisplatin chemotherapy. His diarrhea persisted despite treatment including loperamide and fasting. However, the diarrhea was successfully prevented when loperamide was given before and after the chemotherapy. To our knowledge, this is the first report of prophylactic approach for the CID with loperamide.
腹泻是多西他赛的常见不良反应,发生率为 20%-40%,严重腹泻发生率为 5%-6%。目前存在几种化疗相关性腹泻(CID)的治疗指南,但CID 的预防措施并不明确。我们描述了一种使用洛哌丁胺预防 CID 的新方法。一名 72 岁男性患者患有 IV 期非小细胞肺癌,在接受多西他赛-顺铂化疗后反复出现腹泻。尽管包括洛哌丁胺和禁食在内的治疗措施均未能缓解其腹泻,但在化疗前后给予洛哌丁胺后,腹泻得到了成功预防。据我们所知,这是首例使用洛哌丁胺预防 CID 的报告。